Form 4: Blueprint Medicines Executive Philina Lee Reports Stock Option Exercises and Share Sales
SEC Form 4 Filing
Philina Lee, Chief Commercial Officer of Blueprint Medicines, executed stock options and sold shares on August 5, 2024, according to a Form 4 filing with the SEC.
Summary
- On August 5, 2024, Philina Lee, the Chief Commercial Officer of Blueprint Medicines, exercised stock options and sold shares of common stock.
- Lee exercised options to acquire a total of 41,913 shares at prices ranging from $36.05 to $86.60.
- Following these transactions, Lee directly owns 34,729 shares of Blueprint Medicines common stock.
- The sales of common stock were executed at a weighted average price of $93.19, with individual transactions ranging from $93.00 to $93.835 per share.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by a company executive; it doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider trading activity.
Industry Context
Form 4 filings are standard disclosures required by the SEC when corporate insiders, like officers and directors, trade their company's stock; these filings provide transparency into insider transactions and can be monitored by investors for insights into management's perspective on the company's value and future prospects.
Stakeholder Impact
- Shareholders may interpret the insider's stock sales as a signal, although option exercises and sales are common for executive compensation.
- The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 02/16/2017 | Grant date of stock option that was fully vested as of the transaction date. |
| 07/03/2017 | Grant date of stock option that was fully vested as of the transaction date. |
| 02/16/2018 | Grant date of stock option that was fully vested as of the transaction date. |
| 03/01/2019 | Grant date of stock option that was fully vested as of the transaction date. |
| 03/01/2020 | Grant date of stock option that was fully vested as of the transaction date. |
| 03/01/2022 | Grant date of stock option that vested with respect to 1/48th of the shares underlying the option on April 1, 2022 and as to an additional 1/48th of the shares underlying the option each month thereafter. |
| 03/01/2023 | Grant date of stock option that vested with respect to 1/48th of the shares underlying the option on April 1, 2023 and as to an additional 1/48th of the shares underlying the option each month thereafter. |
| 08/05/2024 | Date of stock option exercises and share sales. |
| 08/07/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.